Can a person take ezetimibe, a statin, and Repatha (alirocumab) together?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can a Person Take Ezetimibe, a Statin, and Repatha Together?

Yes, a person can absolutely take ezetimibe, a statin, and Repatha (alirocumab) together—this triple combination therapy is explicitly recommended and FDA-approved for patients with high cardiovascular risk who need aggressive LDL-C lowering. 122

Evidence-Based Rationale

The 2026 ACC/AHA guidelines provide the strongest and most recent evidence supporting this combination. For adults with clinical ASCVD at very high risk on maximally tolerated statin therapy, ezetimibe and/or a PCSK9 monoclonal antibody (like Repatha) should be added to achieve LDL-C goals <55 mg/dL and non-HDL-C <85 mg/dL. 1 This is a Class 1 (strongest) recommendation with Level A evidence.

The FDA labeling for ezetimibe explicitly states it is indicated "in combination with a statin, and other LDL-C lowering therapies" for reducing elevated LDL-C levels. 22 This directly encompasses the use of PCSK9 inhibitors like Repatha alongside statins.

Clinical Algorithm for Triple Therapy

When to use all three medications together:

  1. Start with maximally tolerated statin therapy as the foundation
  2. Add ezetimibe if LDL-C remains ≥70 mg/dL (1.8 mmol/L) in high-risk patients or ≥55 mg/dL (1.4 mmol/L) in very high-risk patients 13
  3. Add Repatha (alirocumab) if LDL-C on statin plus ezetimibe remains ≥100 mg/dL (2.6 mmol/L) or if the patient hasn't reached their goal 33

Very high-risk criteria include: history of multiple major ASCVD events (recent ACS, prior MI, ischemic stroke, symptomatic PAD) or one major ASCVD event plus multiple high-risk conditions (age >65, coronary revascularization, current smoking, diabetes, heart failure, hypertension, LDL-C >100 mg/dL despite statin + ezetimibe). 1

Safety Profile

This triple combination is safe and well-tolerated. Multiple international guidelines (Canadian Cardiovascular Society, European Society of Cardiology, NICE) all endorse this sequential add-on approach without safety concerns. 33333

The most common adverse events are:

  • Injection site reactions with Repatha (typically mild-moderate)
  • Upper respiratory infections, diarrhea, arthralgia with ezetimibe (similar to placebo rates) 2
  • No significant increase in serious adverse events with combination therapy 456

Key Clinical Pearls

Dosing flexibility: Repatha can be started at 75 mg every 2 weeks and uptitrated to 150 mg every 2 weeks if LDL-C goals aren't met at 8 weeks. 78 This allows individualized therapy based on response.

Timing consideration: If the patient is also on a bile acid sequestrant, administer ezetimibe ≥2 hours before or ≥4 hours after the sequestrant to avoid reduced absorption. 2

Cost and access: While the combination is medically appropriate, PCSK9 inhibitors like Repatha are expensive. However, the 2026 guidelines explicitly state that selection should be "based on degree of LDL-C lowering needed and patient preference," acknowledging this reality. 1

Evidence Quality

The recommendation for triple therapy is supported by:

  • Class 1, Level A evidence from the most recent 2026 ACC/AHA guidelines 1
  • Consistent endorsement across multiple international guidelines (ESC/EAS, Canadian, NICE) 33333
  • FDA approval explicitly permitting this combination 22
  • Clinical trial data demonstrating superior LDL-C reduction with combination therapy versus monotherapy 9510

The evidence overwhelmingly supports that this triple combination is not only safe but represents optimal evidence-based therapy for high-risk patients requiring aggressive lipid lowering to reduce cardiovascular morbidity and mortality.

References

Research

Ezetimibe-Statin Combination Therapy.

Deutsches Arzteblatt international, 2016

Research

Effect of Alirocumab Monotherapy vs Ezetimibe Plus Statin Therapy on LDL-C Lowering in Veterans With History of ASCVD.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2024

Related Questions

What are appropriate alternative statins or non‑statin lipid‑lowering agents for a patient who cannot use rosuvastatin?
For a patient who has adverse reactions to Repatha (alirocumab), ezetimibe, and statins, what other lipid‑lowering treatment options are available?
What are alternative therapies to statins for lowering LDL cholesterol in patients who cannot tolerate statins?
What are suitable alternatives to rosuvastatin for a patient with constipation who is already taking fenofibrate and needs LDL‑cholesterol reduction?
What are the alternatives to Atorvastatin (Lipitor)?
Should a newborn with fever associated with oligohydramnios be treated with empiric antibiotics?
What is the risk of acquiring oral HPV from a single deep kiss with one partner during adolescence before receiving the HPV vaccine?
Can a 40-year-old develop musculoskeletal (MSK) back pain after sleeping on a floor?
In a 25-year-old woman with no history of sexual contact who is anxious about possible non‑sexual HPV transmission, should she be tested for oral HPV or receive the HPV vaccine?
How can influenza be clinically distinguished from upper respiratory tract infections such as acute nasopharyngitis (common cold)?
Can Adderall XR (amphetamine mixed salts extended‑release) be taken twice daily, and if a single daily dose is insufficient, should the total dose be increased or an immediate‑release amphetamine be added in the afternoon, and when is it appropriate to switch to Vyvanse (lisdexamfetamine)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.